Jefferies Increases Chemours Price Target to $17 Citing Opteon Support; Firm Keeps Hold Rating
Jefferies raised its 12-month price target on Chemours Co. (NYSE: CC) to $17 from $14 while retaining a Hold rating, citing support from the company's Opteon product line despite weaker-than-expected fourth-quarter results and cautious near-term guidance. Chemours reported Q4 EBITDA of $128 million, missed consensus and Jefferies' forecasts by $13 …